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Short-Course Antimicrobial Therapy for Intraabdominal Infection
To the Editor: Sawyer and colleagues (May 21 
issue)1 report the findings of the Study to Opti-
mize Peritoneal Infection Therapy (STOP-IT) trial. 
A strength of this study was the freedom afford-
ed to clinicians in the selection of antibiotic regi-
mens, as long as the choice met Surgical Infec-
tion Society–Infectious Diseases Society of America 
(SIS–IDSA) guidelines. International guidelines 
vary with respect to recommended regimens for 
intraabdominal infection2,3; this variation partly 
reflects differences in patterns of antimicrobial 
resistance worldwide.
Data on the most commonly used antimicro-
bial agents and culture isolates in the trial are 
presented in Table S1 in the Supplementary 
Appendix (available with the full text of the article 
at NEJM.org), but it would be of value to under-
stand these in more detail, to help clinicians, in 
particular those outside North America, translate 
the findings of the trial into clinical practice.
Given the flexibility afforded with respect to 
first-line therapy, can the authors provide more 
details on which specific empirical regimens 
were used in the study? In particular, it would be 
informative to know the percentage of culture 
isolates that were susceptible to the initial anti-
microbial regimen and how frequently therapy 
was switched because of resistance. Given the 
brief duration of treatment in the experimental 
group, was a mismatch between the choice of 
the initial antimicrobial drug and organism sus-
ceptibility associated with worse outcomes?
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To the Editor: Sawyer et al. find that a short 
course of antimicrobial therapy (4±1 calendar 
days) was as efficient as an antibiotic treatment 
guided by a clinical approach with respect to the 
occurrence of surgical-site infections, recurrent 
intraabdominal infections, or death. We would 
like to focus on some points of concern. As de-
signed in the study, this strategy cannot be ex-
trapolated to patients with an inadequate source-
control procedure. The authors did not report the 
proportion of included patients with severe sep-
sis, septic shock, or both; mortality among these 
patients is close to 25%.1 The mortality in this 
study (0.8 to 1.2%) suggests that only patients 
with uncomplicated intraabdominal infections 
were involved. Can the study findings be extrap-
olated to antifungal therapy in Candida albicans 
infections (11.2% of the isolated pathogens in 
the control group and 7.0% of the isolated patho-
gens in the experimental group in this study), 
given that in such patients the isolation of can-
dida has been considered to be a risk factor for 
death? 2 In any case, this study should lead phy-
sicians to be more cost-effective in their daily 
practice.
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The Authors Reply: To allow for easier partici-
pation across multiple sites, details regarding 
antimicrobial susceptibility were not recorded, 
and thus our ability to retrospectively determine 
the adequacy of empirical therapy is limited. As 
Marks and Pollara point out, in an attempt to 
limit inadequate initial therapy, participants in 
the STOP-IT trial were allowed to use any em-
pirical agent that complied with SIS–IDSA guide-
lines.1 However, although the focus on empirical 
therapy is understandable, it may not be relevant. 
Bloos et al. found that for patients requiring sur-
gical source control, the only independent risk 
factor for death at 28 days was a delay in source 
control of more than 6 hours. Neither the timing 
of antimicrobial initiation nor the adequacy of 
empirical treatment was associated with mortal-
ity on multivariable analysis.2 Our group at the 
University of Virginia has found similar results.3 
Regardless, clinicians outside North America 
should use local guidelines when considering 
empirical therapy.
In response to Roger et al.: our study was 
limited to the duration of antimicrobial therapy 
after diagnosis and source control. Therefore, 
not only can our results not be applied to pa-
tients with inadequate source control, but they 
also should not be used as evidence for or 
against specific programs to monitor for infec-
tions. The STOP-IT trial did not limit the severity 
of illness required for enrollment. Subsequently, 
the Acute Physiology and Chronic Health Eval-
uation II scores in this trial ref lect wide vari-
ability in the presentation of intraabdominal 
infections. This inclusion makes our results 
more generalizable but less applicable to spe-
cific cases such as severe infections and fungal 
infections.
There is a tendency in the discussion of infec-
tious disease to forget, or rather downplay, that 
an intraabdominal infection is a surgical dis-
ease. Source control, through percutaneous or 
surgical intervention, is the primary treatment 
for these patients. Antimicrobial therapy plays 
an important, albeit secondary, role. Our trial 
highlights this point by showing that, in pa-
tients with adequate source control, the duration 
of antimicrobial therapy can be halved without 
any clinically significant change in outcomes.
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Causality and Chance in the Development of Cancer
To the Editor: Luzzatto and Pandolfi (July 2 is-
sue)1 highlight the combined role of stem-cell 
turnover, stochastic mutation, and environmen-
tal mutagens in the development of cancer. They 
note the low prevalence of cancer of the small 
bowel, despite the size of the organ and rapid 
epithelial turnover. However, among patients with 
Crohn’s disease, the risk of small-bowel adeno-
carcinoma is 20 to 30 times that among patients 
without Crohn’s disease.2 This disparity in rates 
illustrates the power of the inflammatory micro-
environment to manipulate an apparently geneti-
cally stable system. Intestinal inflammation pro-
vides a proliferative drive, provokes intestinal 
stem-cell turnover, and may induce progenitor-
cell dedifferentiation and intestinal dysbiosis; 
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